In clinical trials1,4Evidence: Smaller human trialsMetabolic and weight

Amycretin1

Also called Zenagamtide1,4

Key takeaway

Amycretin, now named zenagamtide, is an experimental Novo Nordisk peptide that activates the receptors for GLP-1 and amylin, two hormones involved in appetite and blood sugar.1,4 It is not FDA-approved. The sources reviewed here describe it only in clinical trials, and none reports an approval in any country.1,4,5,6,7,8,9,10 Published randomized trials report weight loss in early studies and lower blood sugar in a Phase 2 diabetes trial, with common gastrointestinal side effects. Each trial had fewer than 300 participants.2,3,4 Novo Nordisk has registered Phase 3 trials of zenagamtide in obesity, type 2 diabetes and cardiovascular disease on ClinicalTrials.gov. None had posted results when PeptideScanner retained the six records cited here.5,6,7,8,9,10

Amycretin at a glance

What it isAn investigational single-molecule agonist of the GLP-1 and amylin receptors from Novo Nordisk. The 2026 Phase 2 report names it zenagamtide (formerly amycretin) and says it also acts on calcitonin receptors.1,4
FDA statusNot FDA-approved. The sources reviewed here describe it only in clinical trials sponsored by Novo Nordisk, including registered Phase 3 trials.1,4,5,6,7,8,9,10
Human evidenceSmaller randomized, placebo-controlled trials: two early trials in adults with overweight or obesity and a Phase 2 trial in type 2 diabetes. Registered Phase 3 trials have not reported results.2,3,4,5,6,7,8,9,10
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is amycretin?

Amycretin is an experimental drug being developed by Novo Nordisk, which ClinicalTrials.gov lists as the sponsor of the trial records cited on this profile.1,5,6,7,8,9,10

A 2026 Lancet report describes zenagamtide, formerly amycretin, as a single molecule that activates the receptors for GLP-1, amylin and calcitonin. Novo Nordisk’s Phase 3 trials are registered under the name zenagamtide.4,5,6,7,8,9,10

How is amycretin thought to work?

The published trial reports describe amycretin as a unimolecular GLP-1 and amylin receptor agonist, meaning one molecule designed to mimic two hormones that help regulate appetite and blood sugar.2,3

The sources reviewed here do not establish how much each receptor contributes to the effects reported in trials.2,4

What do human studies show?

A first-in-human randomized, placebo-controlled trial in 144 adults with overweight or obesity was designed mainly to assess safety. Adverse events were mild or moderate, and gastrointestinal events were common.2

In a randomized Phase 1b/2a trial in 125 adults with overweight or obesity lasting up to 36 weeks, estimated weight reductions were greater with amycretin than placebo; gastrointestinal events were common and many participants withdrew.3

In a 36-week randomized, placebo-controlled Phase 2 trial in 262 adults with type 2 diabetes, HbA1c, a measure of long-term blood sugar, improved more with the drug than with placebo. Gastrointestinal adverse events were common.4

These were short trials with mostly safety or blood-sugar outcomes, and they do not show long-term benefits or rare harms.2,3,4

The Phase 3 trials registered under the name zenagamtide had not reported results when PeptideScanner retained their ClinicalTrials.gov records: two were recruiting and four were not yet recruiting.5,6,7,8,9,10

What the evidence base contains

  • Controlled human trial A first-in-human, double-blind, randomized, placebo-controlled Phase 1 trial in 144 adults with overweight or obesity, designed mainly to assess safety.2
  • Controlled human trial A randomized, placebo-controlled Phase 1b/2a trial in 125 adults with overweight or obesity at one research center, lasting up to 36 weeks.3
  • Controlled human trial A 36-week double-blind, randomized, placebo-controlled Phase 2 trial in which 262 adults with type 2 diabetes were randomized, published in The Lancet in 2026.4
  • Registered trial without results Six randomized Phase 3 trials of zenagamtide sponsored by Novo Nordisk and registered on ClinicalTrials.gov, none with posted results.5,6,7,8,9,10

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is amycretin FDA-approved?

No. Amycretin remains in clinical trials. None of the sources reviewed here reports an approval of amycretin or zenagamtide in any country.1,4,5,6,7,8,9,10

A Novo Nordisk trial in Japanese men with obesity is listed on ClinicalTrials.gov as completed, in a record last updated on March 5, 2025.1

The 2026 Phase 2 report was published under the name zenagamtide and describes it as formerly amycretin.4

ClinicalTrials.gov lists Novo Nordisk Phase 3 trials of zenagamtide in weight management. AMAZE 9 and AMAZE 13 compare it with placebo for weight loss in adults with obesity or overweight, the second in Asia, and AMBIENCE compares it with placebo in about 8,500 people with cardiovascular disease and overweight or obesity, with major cardiovascular events as its main outcome.5,6,8

Three further Phase 3 trials in type 2 diabetes measure HbA1c: AMBITION 1 and AMBITION 2 compare zenagamtide with placebo, the second in people who also have chronic kidney disease, and AMBITION 7 compares it with insulin glargine in people at increased cardiovascular risk. The registry records were last updated between September 1 and November 12, 2026.7,9,10

Registering a trial does not show that a drug works or is safe.5,6,7,8,9,10

Timeline

  1. Results of the first two randomized amycretin trials are published in The Lancet.2,3
  2. ClinicalTrials.gov updates the record of a completed Novo Nordisk amycretin trial in Japanese men.1
  3. Results of a Phase 2 trial in type 2 diabetes are published under the name zenagamtide.4
  4. ClinicalTrials.gov first posts AMAZE 13, the earliest-registered of the Phase 3 zenagamtide trials cited here.5
  5. ClinicalTrials.gov first posts AMBITION 1 and AMBITION 2, Phase 3 zenagamtide trials in type 2 diabetes.9,10

What is still unknown?

Whether its effects on weight and blood sugar hold up in larger, longer trials: the published trials lasted up to 36 weeks and had fewer than 300 participants each.2,3,4

Its long-term safety and effects on outcomes such as heart disease, which the published trials did not measure.2,3,4

What the Phase 3 trials will find: ClinicalTrials.gov lists their estimated primary completion dates between 2028 and 2030.5,6,7,8,9,10

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Amycretin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Amycretin are the records PeptideScanner has selected and published, not every registration or paper about Amycretin. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

In clinical trials; not FDA-approved. Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects. Phase 3 trials registered as zenagamtide have not reported results.↗↗↗↗↗↗↗↗↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 2.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

Five selected reports cover early oral and subcutaneous amycretin studies, later phase 2 diabetes reports using the name zenagamtide, and a renal-function pharmacokinetic study. The two phase 2 reports describe separate route cohorts within one registered protocol.↗↗↗↗↗

What the reviewed sources report

Early trials reported weight reductions but were designed primarily to assess safety and tolerability. Later zenagamtide studies reported improved glycated hemoglobin in type 2 diabetes. Gastrointestinal adverse events and study discontinuations matter when interpreting these findings.↗↗↗↗

What remains unresolved?

  • How durable are effects after treatment ends, and what do longer studies show about serious harms?↗↗↗↗
  • How do results differ by formulation, population, attrition and the analysis of missing outcomes?↗↗↗↗

Read study designs, results, limitations, and sources →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Amycretin?

Manually reviewed September 15, 2026 · version 2

Browse all Human Evidence Reviews · Open preserved synthesis version 2 →

Five selected reports cover early oral and subcutaneous amycretin studies, later phase 2 diabetes reports using the name zenagamtide, and a renal-function pharmacokinetic study. The two phase 2 reports describe separate route cohorts within one registered protocol.12345

Bottom line from this bounded source set

Early trials reported weight reductions but were designed primarily to assess safety and tolerability. Later zenagamtide studies reported improved glycated hemoglobin in type 2 diabetes. Gastrointestinal adverse events and study discontinuations matter when interpreting these findings.1234

Reviewed study record

Oral amycretin: first-in-human study

Design

A blinded randomized placebo-controlled phase 1 study contained several escalating-exposure parts.1

Population

The study enrolled 144 adults with overweight or obesity across its parts.1

Outcomes reported

Treatment-emergent adverse events were reported in 89 participants and were mild or moderate; gastrointestinal events were common.1

Limitations

Safety was the primary endpoint; weight-related measures were exploratory. Small cohorts and short follow-up do not establish long-term clinical benefit or safety.1

Reviewed study record

Subcutaneous amycretin: phase 1b/2a study

Design

A randomized placebo-controlled multipart study assessed safety and secondary body-weight changes over up to 36 weeks.2

Population

The study randomized 125 adults with overweight or obesity at one research center.2

Outcomes reported

Estimated weight reductions were greater with amycretin. Gastrointestinal events were common, and the authors reported many study withdrawals.2

Limitations

Primary endpoints concerned adverse events. Small cohorts, different observation lengths and substantial attrition limit comparisons and interpretation of weight estimates.2

Reviewed study record

Oral zenagamtide: phase 2 diabetes cohort

Design

A blinded randomized placebo-controlled study assessed 36-week glycated hemoglobin change under NCT06542874.3

Population

This report included 186 adults with type 2 diabetes receiving metformin with or without an SGLT2 inhibitor.3

Outcomes reported

All three active groups improved glycated hemoglobin compared with placebo. Gastrointestinal events were common; seven participants in active groups had serious adverse events.3

Limitations

The primary analysis used on-treatment data without rescue medication. Glycemic improvement does not establish reduction in long-term complications; this cohort shares a protocol with the subcutaneous report.3

Reviewed study record

Subcutaneous zenagamtide: phase 2 diabetes cohort

Design

A blinded randomized placebo-controlled study assessed 36-week glycated hemoglobin change under NCT06542874.4

Population

This route cohort randomized 262 adults with type 2 diabetes; 261 received treatment.4

Outcomes reported

Active groups improved glycated hemoglobin compared with placebo. Gastrointestinal adverse events were common; serious adverse events were reported in active and placebo groups.4

Limitations

This is a route cohort within the same protocol as the oral report, not evidence from an unrelated replication. Follow-up and surrogate endpoints limit conclusions about long-term outcomes.4

Reviewed study record

Renal-function pharmacokinetic study

Design

A single-exposure study compared pharmacokinetics across renal-function groups with four weeks of follow-up, registered as NCT06559527.5

Population

Forty-two adults participated: 14 with normal renal function and seven each with mild, moderate or severe impairment or end-stage renal disease.5

Outcomes reported

The authors reported broadly comparable exposure measurements across groups. Treatment-emergent adverse events occurred in 30 of 42 participants; none were serious or severe, and most were mild gastrointestinal events.5

Limitations

Small groups, one exposure and short follow-up do not establish long-term safety or therapeutic benefit in people with kidney disease. The report does not support individualized treatment recommendations.5

Reviewed source set

  1. PubMed · 40550229Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. ↗PubMed PMID 40550229 · EFetch XML reviewed 2026-09-15 · payload SHA-256 54e5149216ac86bce906130f2c186b95c201d99d222e6af2f785c610e72e3137
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(25)01176-6. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 40550231Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. ↗PubMed PMID 40550231 · EFetch XML reviewed 2026-09-15 · payload SHA-256 e7375cc3b76d64492e736999fb294aa940d3a369b35d3e0f5fc7c59514bf5c80
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(25)01185-7. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  3. PubMed · 42532079Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. ↗PubMed PMID 42532079 · EFetch XML reviewed 2026-09-15 · payload SHA-256 a38bd67eb9127a41fddef95e4d6e879023591b667ddbfd8eb6531901dc42557b
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(26)01247-x. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  4. PubMed · 42532080Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. ↗PubMed PMID 42532080 · EFetch XML reviewed 2026-09-15 · payload SHA-256 bd2779fa1150d5ab1787f5a245e06368e1aa73edf5c6310f340e154d500e222e
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(26)01248-1. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  5. PubMed · 42443140Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide. ↗PubMed PMID 42443140 · EFetch XML reviewed 2026-09-15 · payload SHA-256 56ff4122a6898bfea6b5969ea65ecd7c4cef6fc282cb69818c791eaba39ba5c6
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1111/dom.71096. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Official-source update

Reviewed 2026-09-19 · Preserved version 1

The injection and oral studies are separate

NCT06064006 records 125 participants in a completed study of subcutaneous NNC0487-0111. NCT06049329 records a separate 36-participant oral study in Japanese men. These populations and routes should not be pooled as one trial. NCT06064006 ↗NCT06049329 ↗

More findings and the sources behind them

Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.

The registered primary questions concerned adverse events

Both records list treatment-emergent adverse events as primary outcomes, with different observation windows across study parts. A weight change reported elsewhere is not automatically the primary endpoint of either registered study. NCT06064006 ↗NCT06049329 ↗

Enrollment was selective

The subcutaneous study enrolled adults aged 18–55 within a specified BMI range and excluded diabetic-range HbA1c. The oral study was restricted to Japanese men. These designs do not establish effects across all ages, diabetes populations or demographic groups. NCT06064006 ↗NCT06049329 ↗

Completion does not supply registry results

Both retrieved records are marked completed but contain no posted summary-results section. This is a registry-specific observation as of September 19, 2026, not a claim that trial publications or other reports do not exist. NCT06064006 ↗NCT06049329 ↗

What remains to be checked

  • Match oral and subcutaneous publications to exact protocols and reconcile their analysis populations.
  • Review later trials and result postings without treating these selected records as a complete development inventory.
Source dates and review coverage

PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.

Open versioned findings and source records →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Primary reports of the named peptide administered in people, including pharmacology and secondary human-sample analyses. Reviews, modeling and preclinical reports remain indexed but are outside this human-administration subset.

24 retrieved · 5 included · 18 excluded · 1 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"amycretin"[Title/Abstract] OR "zenagamtide"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:57:48.291244+00:00 · HTTP 200 · SHA-256 fe0d181acf868f0104b711b5845cc6a3acb45e797c2c75a42a58ee55f28eefa8.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:57:49.699244+00:00 · HTTP 200 · SHA-256 1bc7520473a00be68abe188000c5a53f7a9ad13735f1bcdd361525402fe741e0.

  • Eligibility decisions use titles and abstracts from the pinned PubMed results; unavailable details remain unresolved rather than inferred.
  • Full-text appraisal, study-family reconciliation, registry history and broader alias/jurisdiction searches remain separate open work.

Showing 24 of 24 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 42532080 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT06542874.
  2. PubMed 42532079 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT06542874.
  3. PubMed 42443140 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT06559527.
  4. PubMed 40550231 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT06064006.
  5. PubMed 40550229 — include: Original administered human study, including route-specific cohorts and renal pharmacokinetics; eligibility does not establish complete appraisal. Study families: NCT05369390.
  6. PubMed 40550232 — unresolved: No abstract in the retained record; the commentary-like title alone is insufficient for a definitive eligibility decision.
  7. PubMed 42673585 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  8. PubMed 42568490 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  9. PubMed 42452898 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  10. PubMed 42444567 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  11. PubMed 42315994 — exclude: Modular chemical assembly and cell assays, not a human amycretin administration study.
  12. PubMed 42208956 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  13. PubMed 42175595 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  14. PubMed 41948476 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  15. PubMed 41850421 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  16. PubMed 41747885 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  17. PubMed 41344603 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  18. PubMed 41255585 — exclude: Synthetic-data reconstruction and computational modeling of prior studies; no new participants receiving amycretin.
  19. PubMed 41054801 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  20. PubMed 40949933 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  21. PubMed 40706446 — exclude: Mice, rats and cell-based experiments, outside the human-administration subset.
  22. PubMed 40206909 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  23. PubMed 40081498 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.
  24. PubMed 39204092 — exclude: Review or meta-analysis of existing evidence, not a new administered human study.

ClinicalTrials.gov search

ClinicalTrials.gov API v2 identity-name search, complete retrieved records. Includes protocols, extensions, combinations and expanded access; these are not all efficacy trials or published outcomes.

27 retrieved · 27 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

amycretin OR zenagamtide OR "NNC0487-0111" OR "NNC0487-0113"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:55:27.795004+00:00 · HTTP 200 · SHA-256 e78f79507abd0f48c62033a52bef89a4aef56de1b4dfdb91e9e7307623bf1b66.

  • Registry identity screening is distinct from appraisal of posted results, protocol history and publication linkage.
  • Other registries and unregistered studies are outside this search.

Showing 25 of 27 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. ClinicalTrials.gov NCT07757087 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07757087.
  2. ClinicalTrials.gov NCT06461039 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06461039.
  3. ClinicalTrials.gov NCT07533175 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07533175.
  4. ClinicalTrials.gov NCT07815067 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07815067.
  5. ClinicalTrials.gov NCT06049329 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06049329.
  6. ClinicalTrials.gov NCT07535307 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07535307.
  7. ClinicalTrials.gov NCT07668414 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07668414.
  8. ClinicalTrials.gov NCT07668401 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07668401.
  9. ClinicalTrials.gov NCT07508020 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07508020.
  10. ClinicalTrials.gov NCT07567001 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07567001.
  11. ClinicalTrials.gov NCT06064006 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06064006.
  12. ClinicalTrials.gov NCT07797335 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07797335.
  13. ClinicalTrials.gov NCT06542874 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06542874.
  14. ClinicalTrials.gov NCT07503210 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07503210.
  15. ClinicalTrials.gov NCT07339423 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07339423.
  16. ClinicalTrials.gov NCT05369390 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT05369390.
  17. ClinicalTrials.gov NCT06559527 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06559527.
  18. ClinicalTrials.gov NCT07571109 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07571109.
  19. ClinicalTrials.gov NCT07121153 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07121153.
  20. ClinicalTrials.gov NCT07571005 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07571005.
  21. ClinicalTrials.gov NCT07509307 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07509307.
  22. ClinicalTrials.gov NCT07400107 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07400107.
  23. ClinicalTrials.gov NCT06820476 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06820476.
  24. ClinicalTrials.gov NCT06478563 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06478563.
  25. ClinicalTrials.gov NCT07720271 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07720271.

FDA search

Exact active-ingredient terms in the openFDA Drugs@FDA endpoint, checked September 15. A zero result describes this indexed query only, not worldwide nonapproval or every FDA document.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"AMYCRETIN" OR products.active_ingredients.name:"ZENAGAMTIDE" OR products.active_ingredients.name:"NNC0487-0111" OR products.active_ingredients.name:"NNC0487-0113"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:54:13.054316+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.

  • This query does not cover all FDA safety communications, labels, compounding proceedings or other regulatory systems.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local identity matching in the pinned EMA medicines metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary matching of reviewed identity terms: ["amycretin", "zenagamtide", "NNC0487-0111", "NNC0487-0113"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

    • Complete source-document appraisal and national European sources remain open.
    • Zero identity matches apply only to these feed fields and terms.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local identity matching in the pinned EMA documents metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary matching of reviewed identity terms: ["amycretin", "zenagamtide", "NNC0487-0111", "NNC0487-0113"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

      • Complete source-document appraisal and national European sources remain open.
      • Zero identity matches apply only to these feed fields and terms.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        EMA search

        Local identity matching in the pinned EMA orphans metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

        0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        Case-insensitive word-boundary matching of reviewed identity terms: ["amycretin", "zenagamtide", "NNC0487-0111", "NNC0487-0113"]

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

        • Complete source-document appraisal and national European sources remain open.
        • Zero identity matches apply only to these feed fields and terms.

        Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          Explore status sources, recent additions, and coverage gaps

          Living status brief

          What is the current status of Amycretin?

          In clinical trials; not FDA-approved. Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects. Phase 3 trials registered as zenagamtide have not reported results.↗↗↗↗↗↗↗↗↗↗

          The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

          Evidence present

          What records are connected here?

          Evidence lanes
          2
          Source years
          2
          Drugs@FDA applications
          0

          These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

          Latest source-dated record

          What changed most recently at a cited source?

          Clinical trials · source date November 12, 2026

          ClinicalTrials.gov record NCT07931495↗Added to PeptideScanner November 15, 2026

          Coverage gaps

          What remains unknown or unsupported?

          PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

          PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

          Explore the Evidence Map and record counts

          Evidence Map v1

          What kinds of records connect to Amycretin?

          Compare collection coverage →

          This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

          9Selected dated records
          13Connected citations
          2Populated source years2025–2026
          2/4Record lanes present

          Registered human studies

          Trial composition

          6 of 6 selected trial records include at least one phase value; 6 of 6 include a status value in the retained structured contract.

          PhasesPhase 3 6
          Status at observationNot yet recruiting 4Recruiting 2

          PubMed bibliography

          Publication composition

          0 of 3 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

          Bibliography fields unavailable here for 3 selected records; the records remain visible as metadata observations.

          Regulatory and publication surfaces

          What is structurally connected?

          Drugs@FDA applications
          0
          FDA Federal Register documents
          0
          DailyMed SPL versions
          0
          Canonical profile
          Published
          Profile structured data
          Published
          Linked dated records
          9

          Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

          Profile publication history and record counts
          Source records by collection · 9 dated records

          Research hub

          Explore the Amycretin evidence record

          Open all 9 records →
          9Dated records
          2Evidence types
          9Cited public sources
          2Source years

          Change ledger

          Recently changed for Amycretin

          Open all 12 events →

          PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

          Profile updated

          Amycretin profile

          We added the six Novo Nordisk Phase 3 trials that ClinicalTrials.gov lists under the name zenagamtide, which the previous version did not describe, from registry records PeptideScanner retained on November 15, 2026.

          PeptideScanner change date
          November 15, 2026
          Evidence lane
          Profile
          Record added

          ClinicalTrials.gov record NCT07668401

          PeptideScanner retained ClinicalTrials.gov record NCT07668401 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was amycretin.

          PeptideScanner change date
          November 15, 2026
          Cited source date
          August 24, 2026
          Evidence lane
          Clinical trials
          Record added

          ClinicalTrials.gov record NCT07720271

          PeptideScanner retained ClinicalTrials.gov record NCT07720271 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was amycretin.

          PeptideScanner change date
          November 15, 2026
          Cited source date
          September 28, 2026
          Evidence lane
          Clinical trials

          Official-source collections

          Source records for Amycretin

          Open the full research atlas →
          ClinicalTrials.gov6

          0 public history versions across these dated registry records; status labels apply only to each cited observation.

          1. NCT07931495Registry update November 12, 2026 · current at observation
          2. NCT07931547Registry update November 12, 2026 · current at observation
          3. NCT07861100Registry update October 6, 2026 · current at observation
          Explore all selected trial records →Explore all public record history →

          Evidence types

          Coverage by source year

          Selected records span July 14, 2025 to November 12, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

          Continue exploring

          Profiles with overlapping source-year coverage

          Open the research atlas →

          These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

          Organizations and trial records named in cited sources

          Organizations named in cited records

          • Novo Nordisk A/S1

          Trial records

          Dated updates connected to this profile · 9

          Updates connected to this profile

          Open the full cross-source timeline →
          1. Clinical trials

            ClinicalTrials.gov record NCT07931495↗

            PeptideScanner retained ClinicalTrials.gov record NCT07931495 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was amycretin.↗

          2. Clinical trials

            ClinicalTrials.gov record NCT07931547↗

            PeptideScanner retained ClinicalTrials.gov record NCT07931547 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was amycretin.↗

          3. Clinical trials

            ClinicalTrials.gov record NCT07861100↗

            PeptideScanner retained ClinicalTrials.gov record NCT07861100 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was amycretin.↗

          4. Clinical trials

            ClinicalTrials.gov record NCT07720271↗

            PeptideScanner retained ClinicalTrials.gov record NCT07720271 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was amycretin.↗

          5. Clinical trials

            ClinicalTrials.gov record NCT07797335↗

            PeptideScanner retained ClinicalTrials.gov record NCT07797335 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-09-01, and PeptideScanner's reviewed identity mapping was amycretin.↗

          6. Clinical trials

            ClinicalTrials.gov record NCT07668401↗

            PeptideScanner retained ClinicalTrials.gov record NCT07668401 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was amycretin.↗

          7. Literature metadata

            PubMed record PMID 40550232↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 40550232 at 2026-07-30T18:22:52.359Z. PubMed recorded a metadata revision date of 2025-09-11 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.↗

          8. Literature metadata

            PubMed record PMID 40550229↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 40550229 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.↗

          9. Literature metadata

            PubMed record PMID 40550231↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 40550231 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.↗

          Citations

          Sources

          Coverage and sources →

          Numbered markers in the text point here. Each link opens the original public record.

          1. 1
            Oral Amycretin in Japanese Men With Obesity · record history version 6 · last update posted 2025-03-05 ↗

            ClinicalTrials.gov · Official source · Source checked July 22, 2026

          2. 2
            Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial (2025) · PMID 40550229 ↗

            The Lancet · Official source · Source checked November 14, 2026

          3. 3
            Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study (2025) · PMID 40550231 ↗

            The Lancet · Official source · Source checked November 14, 2026

          4. 4
            Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial (2026) · PMID 42532080 ↗

            The Lancet · Official source · Source checked November 14, 2026

          5. 5
            ClinicalTrials.gov record NCT07668401 · retained source version 2026-08-24:5833a93b62ac59e564069a1fd4bf8cd19222029a0b3f7ce99899f59f22b177dc ↗

            ClinicalTrials.gov · Official source · Source checked November 15, 2026

          6. 6
            ClinicalTrials.gov record NCT07720271 · retained source version 2026-09-28:93ed8b5caeb775d7d6fbd3c0d4e0c5ce26698ea8c1ae70efd4b447411785d74d ↗

            ClinicalTrials.gov · Official source · Source checked November 15, 2026

          7. 7
            ClinicalTrials.gov record NCT07797335 · retained source version 2026-09-01:bc9e4b3246b2a07cc90834c13fa40cb6e95033b38aa14b8b29396518aff35b74 ↗

            ClinicalTrials.gov · Official source · Source checked November 15, 2026

          8. 8
            ClinicalTrials.gov record NCT07861100 · retained source version 2026-10-06:c1032ee418d61646c75ff354e74a7285b9376c0eaeb82c0622036ec003177db0 ↗

            ClinicalTrials.gov · Official source · Source checked November 15, 2026

          9. 9
            ClinicalTrials.gov record NCT07931495 · retained source version 2026-11-12:23a664ffa2bff21e8dd34305b3456a3ee5f65f216d24ab4d40b786451213bde4 ↗

            ClinicalTrials.gov · Official source · Source checked November 15, 2026

          10. 10
            ClinicalTrials.gov record NCT07931547 · retained source version 2026-11-12:2d2f13db63aaf8b3fc36fdb710419bcd545343ee84a805e746017fc30430e350 ↗

            ClinicalTrials.gov · Official source · Source checked November 15, 2026